Senti Biosciences, Inc. announced strategic plan to focus research and development efforts on lead oncology candidate SENTI-202 for the treatment CD33 and/or FLT3 expressing hematologic malignancies including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), to continue to advance SENTI-401 through preclinical studies to target colorectal cancer and other CEA-positive solid tumors, and to pursue strategic geographic partnerships for clinical development of SENTI-301A for liver cancer, of which there is high prevalence in Asian territories.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2787 USD | -0.78% | -9.37% | -57.77% |
1st Jan change | Capi. | |
---|---|---|
-57.77% | 13.27M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- SNTI Stock
- News Senti Biosciences, Inc.
- Senti Biosciences, Inc. Announces Strategic Plan to Focus Research and Development Efforts on Lead Oncology Candidate SENTI-202